Comparative Pharmacology
Head-to-head clinical analysis: FARYDAK versus ZOLINZA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FARYDAK versus ZOLINZA.
FARYDAK vs ZOLINZA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Panobinostat is a histone deacetylase (HDAC) inhibitor that inhibits the enzymatic activity of HDACs, leading to accumulation of acetylated histones and other proteins, resulting in cell cycle arrest and apoptosis in cancer cells.
Histone deacetylase (HDAC) inhibitor; inhibits class I and II HDAC enzymes, leading to accumulation of acetylated histones and non-histone proteins, inducing cell cycle arrest and apoptosis in malignant cells.
20 mg orally once daily on days 1, 8, and 15 of a 28-day cycle.
400 mg orally once daily with food.
None Documented
None Documented
Terminal elimination half-life is approximately 50 hours (range 31-67 hours), supporting once-weekly dosing.
The terminal elimination half-life is approximately 2 hours. Due to its short half-life, vorinostat requires twice-daily dosing to maintain therapeutic concentrations.
Primarily hepatic metabolism via CYP3A4, with <5% excreted unchanged in urine and <1% in feces.
Zolinza (vorinostat) is primarily metabolized via glucuronidation and hydrolysis; renal excretion of unchanged drug is minimal (<1%). Approximately 52% of the dose is recovered in urine as metabolites, and about 43% in feces as metabolites and parent drug.
Category C
Category C
Histone Deacetylase Inhibitor
Histone Deacetylase Inhibitor